


## Tacrine

<b>Cat. No.:</b>	HY-111338
<b>CAS No.:</b>	321-64-2
<b>Molecular Formula:</b>	C <sub>13</sub> H <sub>14</sub> N <sub>2</sub>
<b>Molecular Weight:</b>	198.26
<b>Target:</b>	Cholinesterase (ChE)
<b>Pathway:</b>	Neuronal Signaling
<b>Storage:</b>	4°C, sealed storage, away from moisture and light * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : ≥ 100 mg/mL (504.39 mM)  
\* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	5.0439 mL	25.2194 mL	50.4388 mL
	5 mM	1.0088 mL	5.0439 mL	10.0878 mL
	10 mM	0.5044 mL	2.5219 mL	5.0439 mL

Please refer to the solubility information to select the appropriate solvent.

#### In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
Solubility: ≥ 2.5 mg/mL (12.61 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)  
Solubility: ≥ 2.5 mg/mL (12.61 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil  
Solubility: 2.5 mg/mL (12.61 mM); Suspended solution; Need ultrasonic

### BIOLOGICAL ACTIVITY

#### Description

Tacrine is a potent acetylcholinesterase (AChE) inhibitor (IC<sub>50</sub>=109 nM), also acting as a CYP1A2 substrate agent. Tacrine exhibits certain hepatotoxicity in some individuals. Tacrine can be used for researching Alzheimer's disease (AD)<sup>[1][2][3]</sup>.

#### IC<sub>50</sub> & Target

AChE

### REFERENCES

---

[1]. Patocka J, et al. Possible role of hydroxylated metabolites of tacrine in drug toxicity and therapy of Alzheimer's disease. *Curr Drug Metab.* 2008;9(4):332-335.

[2]. Bhatt S, et al. Assessment of the CYP1A2 Inhibition-Mediated Drug Interaction Potential for Pinocebrin Using In Silico, In Vitro, and In Vivo Approaches. *ACS Omega.* 2022;7(23):20321-20331. Published 2022 Jun 2.

[3]. Romero A, et al. Novel tacrine-related drugs as potential candidates for the treatment of Alzheimer's disease. *Bioorg Med Chem Lett.* 2013;23(7):1916-1922.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA